<p>OraSure Technologies, Inc. (NASDAQ:OSUR - 獲取免費報告) 的股價在週二的交易中突破了其 200 日移動平均線。該股票的 200 日移動平均價為 2.82 美元，最高交易價達到 3.01 美元。OraSure Technologies 的股票最後交易價為 2.86 美元，成交量為 506,349 股。</p>
<p>獲取 <strong>OraSure Technologies</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>OSUR 已成為幾份研究分析師報告的主題。Stephens 在 11 月 12 日的研究報告中將 OraSure Technologies 的目標價從 3.50 美元下調至 3.00 美元，並對該股票給予 “持平” 評級。Weiss Ratings 在 1 月 22 日的報告中重新發布了對 OraSure Technologies 的 “賣出 (d)” 評級。兩位分析師對該股票給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “減持”，共識目標價為 3.00 美元。</p>
<p><strong>查看我們最新的 OSUR 股票報告</strong></p>
<h2>OraSure Technologies 股價下跌 2.1%</h2>
<p>該股票的市值為 2.0515 億美元，市盈率為-3.58，貝塔值為 0.87。該公司的 50 日移動平均價格為 2.55 美元，200 日移動平均價格為 2.82 美元。</p>
<p>OraSure Technologies (NASDAQ:OSUR - 獲取免費報告) 最近在 11 月 5 日公佈了其財報。這家醫療儀器供應商報告季度每股收益為 (-0.13) 美元，超出分析師一致預期的 (-0.16) 美元，超出幅度為 0.03 美元。OraSure Technologies 的淨利潤率為-47.92%，股本回報率為-13.61%。該業務在本季度的收入為 2709 萬美元，而分析師預期為 2896 萬美元。平均而言，賣方分析師預計 OraSure Technologies, Inc.在當前年度的每股收益為-0.08 美元。</p>
<h2>對 OraSure Technologies 的對沖基金看法</h2>
<p>幾家機構投資者和對沖基金最近買入和賣出了 OSUR 的股票。Farther Finance Advisors LLC 在第二季度購買了 OraSure Technologies 的新股份，價值約 26,000 美元。Prudential Financial Inc.在第二季度購買了 OraSure Technologies 的新頭寸，價值約 31,000 美元。Nierenberg Investment Management Company Inc.在第二季度購買了 OraSure Technologies 的新頭寸，價值約 35,000 美元。L2 Asset Management LLC 在第二季度購買了 OraSure Technologies 的新股份，價值約 39,000 美元。最後，Coldstream Capital Management Inc.在第二季度將其在 OraSure Technologies 的持股增加了 128.2%。Coldstream Capital Management Inc.現在擁有 13,308 股該醫療儀器供應商的股票，價值 40,000 美元，此前在上個季度又收購了 7,477 股。目前 93.50% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>OraSure Technologies 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>OraSure Technologies, Inc.是一家位於賓夕法尼亞州貝塞勒姆的診斷和醫療設備公司，專注於開發、製造和商業化即時檢測和自我檢測產品。成立於 1988 年，OraSure 建立了一系列口腔液體和其他非侵入性樣本採集技術，以支持傳染病、藥物濫用以及健康和保健生物標誌物的檢測。</p>
<p>該公司的旗艦產品 OraQuick®快速 HIV 測試是首個獲得美國食品和藥物管理局批准的非處方口腔液體 HIV-1/2 抗體檢測。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 OraSure Technologies 更好</li>
<li>你的銀行賬户不再安全</li>
<li>Ray Dalio 説買黃金。我説每月從中獲利</li>
<li>每天一次 1 小時</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>他們剛剛試圖殺死黃金</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 OraSure Technologies 嗎？</h2>
<p>在考慮 OraSure Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 OraSure Technologies 並不在名單上。</p>
<p>雖然 OraSure Technologies 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

奧瑞許科技

<p>OraSure Technologies（納斯達克代碼：OSUR）股票突破了其 200 日移動平均線 2.82 美元，最高交易價達到 3.01 美元，最終收於 2.86 美元。分析師設定的共識目標價為 3.00 美元，評級包括兩個持有和一個賣出。該公司報告的季度每股收益為（0.13 美元），超出預期，但淨利潤率為負的 47.92%。機構投資者持有 93.50% 的股份。OraSure 專注於診斷和醫療設備，特別是 OraQuick®快速 HIV 檢測</p>

<p>OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.82 and traded as high as $3.01. OraSure Technologies shares last traded at $2.86, with a volume of 506,349 shares changing hands.</p>
<div class="lb-trans"><p>OraSure Technologies, Inc. (NASDAQ:OSUR - 獲取免費報告) 的股價在週二的交易中突破了其 200 日移動平均線。該股票的 200 日移動平均價為 2.82 美元，最高交易價達到 3.01 美元。OraSure Technologies 的股票最後交易價為 2.86 美元，成交量為 506,349 股。</p>
</div><p>Get <strong>OraSure Technologies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>OraSure Technologies</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>OSUR has been the topic of several research analyst reports. Stephens lowered their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Wednesday, November 12th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Reduce&#34; and a consensus target price of $3.00.</p>
<div class="lb-trans"><p>OSUR 已成為幾份研究分析師報告的主題。Stephens 在 11 月 12 日的研究報告中將 OraSure Technologies 的目標價從 3.50 美元下調至 3.00 美元，並對該股票給予 “持平” 評級。Weiss Ratings 在 1 月 22 日的報告中重新發布了對 OraSure Technologies 的 “賣出 (d)” 評級。兩位分析師對該股票給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “減持”，共識目標價為 3.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on OSUR</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 OSUR 股票報告</strong></p>
</div><h2>OraSure Technologies Trading Down 2.1%</h2>
<div class="lb-trans"><h2>OraSure Technologies 股價下跌 2.1%</h2>
</div><p>The stock has a market cap of $205.15 million, a P/E ratio of -3.58 and a beta of 0.87. The company's 50 day moving average price is $2.55 and its two-hundred day moving average price is $2.82.</p>
<div class="lb-trans"><p>該股票的市值為 2.0515 億美元，市盈率為-3.58，貝塔值為 0.87。該公司的 50 日移動平均價格為 2.55 美元，200 日移動平均價格為 2.82 美元。</p>
</div><p>OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. OraSure Technologies had a negative net margin of 47.92% and a negative return on equity of 13.61%. The business had revenue of $27.09 million during the quarter, compared to analysts' expectations of $28.96 million. On average, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.</p>
<div class="lb-trans"><p>OraSure Technologies (NASDAQ:OSUR - 獲取免費報告) 最近在 11 月 5 日公佈了其財報。這家醫療儀器供應商報告季度每股收益為 (-0.13) 美元，超出分析師一致預期的 (-0.16) 美元，超出幅度為 0.03 美元。OraSure Technologies 的淨利潤率為-47.92%，股本回報率為-13.61%。該業務在本季度的收入為 2709 萬美元，而分析師預期為 2896 萬美元。平均而言，賣方分析師預計 OraSure Technologies, Inc.在當前年度的每股收益為-0.08 美元。</p>
</div><h2>Hedge Funds Weigh In On OraSure Technologies</h2>
<div class="lb-trans"><h2>對 OraSure Technologies 的對沖基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of OSUR. Farther Finance Advisors LLC purchased a new stake in OraSure Technologies in the second quarter worth about $26,000. Prudential Financial Inc. purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $31,000. Nierenberg Investment Management Company Inc. bought a new position in shares of OraSure Technologies during the 2nd quarter valued at approximately $35,000. L2 Asset Management LLC purchased a new stake in OraSure Technologies in the 2nd quarter worth approximately $39,000. Finally, Coldstream Capital Management Inc. increased its holdings in OraSure Technologies by 128.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 7,477 shares in the last quarter. 93.50% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買入和賣出了 OSUR 的股票。Farther Finance Advisors LLC 在第二季度購買了 OraSure Technologies 的新股份，價值約 26,000 美元。Prudential Financial Inc.在第二季度購買了 OraSure Technologies 的新頭寸，價值約 31,000 美元。Nierenberg Investment Management Company Inc.在第二季度購買了 OraSure Technologies 的新頭寸，價值約 35,000 美元。L2 Asset Management LLC 在第二季度購買了 OraSure Technologies 的新股份，價值約 39,000 美元。最後，Coldstream Capital Management Inc.在第二季度將其在 OraSure Technologies 的持股增加了 128.2%。Coldstream Capital Management Inc.現在擁有 13,308 股該醫療儀器供應商的股票，價值 40,000 美元，此前在上個季度又收購了 7,477 股。目前 93.50% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>OraSure Technologies Company Profile</h2>
<div class="lb-trans"><h2>OraSure Technologies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.</p>
<div class="lb-trans"><p>OraSure Technologies, Inc.是一家位於賓夕法尼亞州貝塞勒姆的診斷和醫療設備公司，專注於開發、製造和商業化即時檢測和自我檢測產品。成立於 1988 年，OraSure 建立了一系列口腔液體和其他非侵入性樣本採集技術，以支持傳染病、藥物濫用以及健康和保健生物標誌物的檢測。</p>
</div><p>The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.</p>
<div class="lb-trans"><p>該公司的旗艦產品 OraQuick®快速 HIV 測試是首個獲得美國食品和藥物管理局批准的非處方口腔液體 HIV-1/2 抗體檢測。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than OraSure Technologies</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>1 Hour Once A Day</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>They just tried to kill gold</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 OraSure Technologies 更好</li>
<li>你的銀行賬户不再安全</li>
<li>Ray Dalio 説買黃金。我説每月從中獲利</li>
<li>每天一次 1 小時</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>他們剛剛試圖殺死黃金</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OraSure Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 OraSure Technologies 嗎？</h2>
</div><p>Before you consider OraSure Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 OraSure Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 OraSure Technologies 並不在名單上。</p>
</div><p>While OraSure Technologies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 OraSure Technologies 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

奧瑞許科技（NASDAQ:OSUR）的股價突破了 200 日移動平均線 - 接下來會如何發展？